Ipsen – improving patient health outcomes


As a mid-sized global biopharmaceutical company, Ipsen improves patients’ lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.



Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.

Author Image

Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.

David Loew




Putting patients at the heart of our work

Our commitment to improving the lives and medical outcomes of patients is the driving force behind every decision made at Ipsen. We believe in working with patients, for patients, listening to their needs and involving their insights in the entire….



Shaping a more sustainable future

Ipsen is dedicated to safeguarding and preserving our planet. The Generation Ipsen ESG responsibility strategy lays out ambitious goals for the company in each of four pillars: Environment, Patients, People and Governance.

Careers at Ipsen

Ipsen offers a multitude of exciting opportunities for talented and motivated people in careers ranging from medial and clinical research to sales, marketing, finance, IT, HR and legal services. We are committed to providing our employees with a workplace that is welcoming, challenging and inclusive.

Top Ipsen stories

31 August 2023 2 mins read
Managing Post-Stroke Spasticity: Hub’s Story

Hub experienced a hemorrhagic stroke in 2021 as a result of bleeding in the brain. Like many stroke survivors, Hub experiences spasticity, a condition in which muscles contract uncontrollably leading to pain, stiffness and limited movement. As a father of…

31 August 2023 2 mins read
Life with FOP: Savannah’s Story

Savannah – or Sassy Savvy as she’s known by her family – is a caring sister, a strong-willed daughter and above all else, overfilling with creativity, happiness and laughter. Savannah is also living with a rare disease, fibrodysplasia ossificans progressiva…

31 August 2023 2 mins read
Caring for a Loved One with Metastatic Pancreatic Cancer: Nora’s Story

Nora and her husband, Hector, met 39 years ago, got married shortly after, and have been inseparable ever since. In 2021, Hector was diagnosed with metastatic pancreatic cancer, which threw their entire family into navigating a very difficult diagnosis. Nora…

31 August 2023 2 mins read
Life with Primary Biliary Cholangitis: Sabrina’s Story

Sabrina is a lover of nature, mother and grandmother, whose outlook on life is to make every moment count. Sabrina lives with primary biliary cholangitis (PBC), which means every day is different depending on the severity of her symptoms, but…

12 May 2023 4 mins read
Understanding the true impact of living with FOP

This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23, we marked FOP Awareness Day to honor…

05 September 2022 5 mins read
‘A Life in a Day’: the realities of living with FOP

I was honored to be invited to take on the challenge to live ‘A Life in a Day of a patient with FOP’ – but also apprehensive. The challenge simulated a day spent living as someone who has fibrodysplasia ossificans…

12 August 2022 1 mins read
Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

25 January 2022 2 mins read
Our pledge: summaries in plain language for all journal publications

Today, we are broadening our commitment to providing everyone with the opportunity to read and understand our research. From July 2022, we will publish, as a minimum, a 250-word plain language summary alongside all company-sponsored journal publications from human studies.